KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ginkgo Bioworks Holdings (DNA) Receivables (2020 - 2025)

Ginkgo Bioworks Holdings' Receivables history spans 6 years, with the latest figure at $14.7 million for Q4 2025.

  • For Q4 2025, Receivables rose 23.92% year-over-year to $14.7 million; the TTM value through Dec 2025 reached $14.7 million, up 23.92%, while the annual FY2025 figure was $14.7 million, 23.92% up from the prior year.
  • Receivables reached $14.7 million in Q4 2025 per DNA's latest filing, down from $21.4 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $178.1 million in Q2 2022 to a low of $370000.0 in Q1 2024.
  • Average Receivables over 5 years is $49.0 million, with a median of $21.8 million recorded in 2025.
  • Peak YoY movement for Receivables: plummeted 99.56% in 2024, then surged 7006.22% in 2025.
  • A 5-year view of Receivables shows it stood at $136.1 million in 2021, then crashed by 98.86% to $1.6 million in 2022, then skyrocketed by 595.89% to $10.8 million in 2023, then increased by 9.63% to $11.9 million in 2024, then grew by 23.92% to $14.7 million in 2025.
  • Per Business Quant, the three most recent readings for DNA's Receivables are $14.7 million (Q4 2025), $21.4 million (Q3 2025), and $22.2 million (Q2 2025).